Agendia at ASCO: What You Need to Know

The critical role of genomic testing for early-stage breast cancer patients will be a major focus at the American Society of Clinical Oncology (ASCO) Annual Meeting. Learn about Agendia’s new study results highlighting MammaPrint®, currently the only FDA-cleared genomic test to provide women of all ages with early-stage breast cancer answers about their risk for cancer recurrence.

 

New Data Shows MammaPrint’s Role in Personalizing Treatment Approaches

New results from the I-SPY 2 and NBRST trials will be presented highlighting the importance of implementing the MammaPrint 70-Gene Breast Cancer Risk of Recurrence and BluePrint 80-Gene Molecular Subtyping tests to inform personalized treatment management decisions for early-stage breast cancer patients.

 

I-SPY 2 – Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer: Follow-up results from the neoadjuvant Phase II I-SPY 2 trial will show that residual cancer burden (RCB) is a prognostic indicator for long-term outcomes in patients pre-selected by the MammaPrint Breast Cancer Risk of Recurrence test.

If you are onsite at ASCO, please visit:

  • Abstract: 520
  • Poster Session: Saturday, June 2, 8:00-11:30 a.m. CDT, Hall A
  • Poster Board #12
  • Poster Discussion Session: Saturday, June 2, 3:00-4:15 p.m. CDT, Hall D11

 

NBRST – Neoadjuvant Breast Registry – Symphony Trial: Results from the prospective, observational NBRST trial suggest using MammaPrint and BluePrint together may identify which molecular subtypes (Basal, HER2, High Risk Luminal B and Low Risk Luminal A) are most responsive to neoadjuvant chemotherapy by both pathological complete response (pCR) rate and long-term survival.

If you are onsite at ASCO, please visit:

  • Abstract: 590
  • Poster Session: Saturday, June 2, 8:00-11:30 a.m. CDT, Hall A
  • Poster Board #822